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“Treatment of Chronic Venous Ulcers with Topical Sucralfate – A 
Prospective Study” 
ABSTRACT 
        Chronic venous ulcer is an important surgical condition due to high 
incidence and lack of standard therapeutic protocols. The care of these is often 
palliative and mostly unsuccessful. A variety of medical therapies to influence 
wound repair and regeneration are currently being investigated. Topical drugs 
have shown promise in this regard. Wound healing is a complex process with 
angiogenesis, cell proliferation, inflammation and re-epithelialization. Thus the 
ideal drug to treat such ulcers should possess properties to enhance all these 
parameters. 
    Sucralfate is a cytoprotective agent, which is used in treatment of GIT related 
diseases like peptic ulcers. Recent studies have shown the stimulating effect of 
sucralfate over EGF expression and other growth factors involved in tissue 
repair. Furthermore, the stimulating effects of sucralfate on vascular factors 
have been demonstrated. Several studies show that sucralfate increases wound 
contraction, re-epithelialization and diminishes inflammatory reactions. It is 
safe as demonstrated by complete lack of side effects. Multiple studies using 
sucralfate for treating epithelial wounds showed encouraging results and served 
as basis for conducting this study. 
    30 patients were randomized into study and control groups and treated with 
topical sucralfate and saline dressings respectively. Parametric analysis of 
decrease in ulcer size, granulation and decrease in pain over ulcer. Majority of 
the study group showed improvement in all parameters while that in control 
group was drastically low. The current study involved a small group of patients 
but showed promising results with decrease in objective and subjective 
symptoms. Sucralfate being an inexpensive drug lessens the need for heavy 
expenditure. We conclude that sucralfate can be one such alternative solution to 
this age old problem and deserves thorough research, exploration and evaluation 
in this regard. 
Key Words: Chronic venous ulcer, sucralfate topical application, wound 
healing, epithelial wounds. 
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“Not all wounds heal, not all scars show” 
     - An age old English philosophical statement. But when we look at the 
history of wounds and wound care, it’s not surprising if one finds this saying apt 
and relevant in this context. Famous French war surgeon Ambroise Parĕ while 
treating a wounded soldier exclaimed “I bandaged him, god treated him”. The 
art and science of wound treatment has come a long way from its philosophical 
and rather religious beginnings and in the present day, it is observing a 
revolution of sorts with the rapidly developing methods of treatments and newer 
inventions. 
    The history of wounds and wound management is as old as mankind itself. 
From the time of cavemen who developed ingenious primitive techniques to 
treat wounds to the sophisticated present day, the field of wound management 
still remains an ever-evolving and extensively researched issue. Management of 
wounds, especially those acute, still pose a great challenge to the surgeons 
worldwide, in spite of numerous treatment options available. Advances in the 
management of wounds have advanced the whole art of surgery. Although the 
causes of injury are most of the times obvious and the wound easily observed, it 
is only in the previous two or three decades that the different processes 
occurring in wound and wound healing as well as the factors influencing them 
have been understood.  
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     Despite that most of the historical concepts of wound healing are based on 
mysticism, empirical logic with  reasoning and unfounded conclusions, there 
was a commendable sense of imagination and brilliance among a few who 
thought objectively and clearly, and were brave enough to defend the new ideas 
spawned in the process. Unfortunately, this new knowledge has not led us to 
significant breakthroughs in the treatment of wounds, as observed usually in 
other areas of surgery. Although much has been accomplished in this regard, the 
pieces have yet to be fit together in a way that it is truly beneficial and 
meaningful to the suffering patient. 
         Though wounds tend to heal naturally irrespective of whether recovery to 
full structural integrity and appropriate functioning is possible, the early man 
noticed that several external factors and herbal remedies assist or hasten the 
process of wound healing. This was followed by the realization of importance 
and absolute requirement of hygiene in a wound environment. The vital finding 
of halting bleeding from a wound gave a new dimension to management of 
wounds. The early healers observed that covered wounds bled less and any 
applied pressure stilled a rather serious haemorrhage. A number of substances, 
by trial and error, were used to soothe pain and perhaps hasten up the healing 
process. 
    The earliest documented evidence of wounds, healing and treatment dates 
back to the early civilizations of Sumeria and Egypt (circa 2000 BC). Healers 
10 
 
and priests started employing physical methods to treat a wound along with 
religious incantations. The Egyptians were the first ones to differentiate infected 
and diseased wounds from non-infected and clean wounds. Concoctions and 
pastes containing antibacterial, absorbent properties like honey, resins and herbs 
were used for treatment of wounds. Cleaning of wounds with fresh water and 
milk was encouraged, emphasising on the fact that the Egyptians possessed a 
sound knowledge of wound irrigation, albeit less scientific. They also made use 
of minerals, like the green copper pigment obtained from malachite and certain 
mercury compounds for application over wounds. These minerals possessed 
powerful astringent and antiseptic properties. 
      Greek medicine borrowed a lot from the exploits of much older Egyptians. 
The early Greek physicians classified wounds into acute and chronic types. 
Hippocrates, the father of western medicine, proposed that contused wounds 
should be treated with salves in order to reduce inflammation. He also stressed 
on the importance of removing necrotic material from the wound in order to 
prevent further infection and promote better healing. Hippocrates also engrained 
the humoral theory of diseases among his contemporaries, thus considering 
wounds as diseases, which require local care as well as bodily humoral balance 
for proper healing. The Greeks also extensively used moist dressings, 
emphasizing on the importance of maintaining a moist environment for better 
healing. It is now proved beyond doubt that moist wounds re-epithelialize at a 
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rate double that of wounds which are kept in a dry environment. These concepts 
of wound debridement and moist dressings are still in vogue.  
    The Romans took over where the Greeks left, with Cornelius Celsus 
describing the four cardinal signs of inflammation and introducing elementary 
suturing techniques for chronic wounds after thorough debridement. He 
established, along with other Roman physicians, that different types of wounds 
need different treatment. Galen of Pergamum advocated polypharmacy along 
with local wound care.  
    There was a significant decrease in advances during the middle ages and 
renaissance period. More recently in the 19
th
 century, antiseptics were a 
significant find in the history of wound healing. Sterile practices and use of 
dressings impregnated with antiseptics and/or antibiotics considerably reduced 
wound infection and promoted better healing. In the mid-20
th
 century the focus 
shifted from trials to evidence based practices and research in the field of 
wound care. The advent of fibrous synthetics like polyethylene, polyvinyl 
compounds and nylon provided new resources from which practitioners in the 
field of wound care could explore better avenues of protecting and treating 
wounds and perhaps even accelerating the natural wound healing process. The 
importance of moist dressings was ‘rediscovered’. This dawn of modern wound 
management initiated a process of improvement in the surgeon’s ability to 
bolster wound-site healing and re-epithelialization. 
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     In the late 20
th
 century, new discoveries and improvements in hybrid and 
composite polymers expanded the spectrum of substances available for dressing 
of wounds. Graft techniques and biotechnology have paved way for production 
of useful protective covering made of actual human skin created through 
cloning procedures. Other recent developments have been the reiterated focus 
on the patient concern of pain. Today, the practice of wound healing not only 
involves local wound care but also manipulation and modulation of wound 
environments by use of inflammatory mediators, cytokines, growth factors and 
bioengineered tissues. A combined and discrete use of all the above will enable 
optimal wound healing. 
 
 
 
 
 
 
 
 
13 
 
OBJECTIVES OF THE STUDY 
   To study the efficacy of topical Sucralfate application over chronic venous 
ulcers with respect to the following parameters: 
• Size of the lesion 
• Granulation 
• Decrease in pain over the ulcer. 
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REVIEW OF LITERATURE 
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    Wound healing is a dynamic and complex sequence of biological events 
aimed at replacing devitalized and destroyed cellular structures and tissue 
layers. It can be described as an interplay of various cellular and biochemical 
processes that ultimately leads to restitution of structural integrity and normal 
functions of any tissue. Individual tissues vary in their healing properties but the 
underlying mechanisms will essentially remain the same. 
    The amalgam of events that make up the well-coordinated process of wound 
healing are intricate and closely orchestrated. The classic model of wound 
healing comprises of sequential, yet overlapping phases with a fairly predictable 
course and defined by characteristic cellular populations and biochemical 
events. The key stages in the procession of wound healing include: 
 Haemostasis  
 Inflammation 
 Proliferation 
 Maturation and remodelling. 
    An analogous system depicts the phases as inflammation, the fibroblastic 
phase, scar maturation and wound contracture. 
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 PHASES OF WOUND HEALING: 
 
HEMOSTASIS: 
    Wounds disrupt tissue integrity leading to damage of vascular structures 
resulting in an outflow of blood and lymphatic fluid. This results in the 
formation of an initial reparative coagulum. Both the extrinsic and intrinsic 
pathways of coagulation cascade are activated by virtue of tissue damage and 
exposure of thrombocytes sub-endothelial collagen and extra cellular matrix 
respectively. 
 
 
FIGURE 1- STAGE OF HEMOSTASIS  
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     A short lived phase of vasoconstriction is observed at this time. The 
thrombocytes also promote aggregation, which temporarily dam the wound. 
Constricted vessels dilate and make way for influx of more thrombocytes and 
other blood cells. This heralds the initiation of the inflammatory phase as well 
as other processes like collagenogenesis, collagenolysis, angiogenesis and re-
epithelialization, indicating the overlapping nature of the healing compendium 
as mentioned earlier. These processes are mediated by a host of growth factors 
and cytokines. 
    Towards the end of this phase, fibrinogen is cleaved into fibrin and the 
coagulation cascade is thus completed. The fibrin clots formed not only aid in 
achieving hemostasis but also serve as structural support in the form of 
scaffolding for migration and deposition of cellular components of 
inflammation into the wound. The hemostatic phase starts immediately after the 
offense has occurred and may continue for several days 
 
INFLAMMATION: 
    The phase of inflammation is construed to consist of an early and late 
components, the early part of which is predominated by the influx of 
polymorphonuclear neutrophils and the latter characterized by invasion of the 
wound by macrophages. The polymorphonuclear neutrophils infiltrate wounds 
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in the first 24- 48 hours of injury. Their primary function is phagocytosis of 
bacteria and tissue debris. They are also a major source of cytokines early 
during inflammation, especially TNF α, as well as proteases such as collagenase 
which partake in ground substance and matrix degradation in the initial phases 
of wound healing. By 72 hours, the neutrophils are either interred in the wound 
scab or sequestered by the macrophages. 
 
 
FIGURE 2- STAGE OF INFLAMMATION  
 
    The second population of inflammatory cells to invade wounds are 
macrophages, which are derived from circulating monocytes. They appear after 
48- 96 hours after injury, and remain present till the healing process is 
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complete. Macrophages, like neutrophils, participate in phagocytosis and 
contribute to microbial stasis via oxygen radical and nitric oxide synthesis. The 
most crucial function of macrophages is activation and recruitment of other 
cells via mediators such as cytokines and growth factors as well as directly by 
cell-cell interactions. Macrophages also play a significant role in regulating 
angiogenesis as well as orchestrate multiplication of smooth muscle cells, 
matrix deposition and remodelling.   
    T-lymphocytes are the third type of inflammatory cells to invade a wound. 
They are seen about a week post injury, although very less in number compared 
to the macrophages. They bridge the transition from inflammatory to the 
proliferative phase of wound healing and play an active role in modulation of 
wound environment. Depletion of lymphocytes decreases wound strength and 
collagen content. It is worthwhile noting that selective depletion of CD8+ 
suppressor T-cells enhance wound healing.  
    As inflammation dies down towards the end of this phase, fewer 
inflammatory mediators are manufactured and released, while the existing ones 
are subjected to disintegration. The number of cells of inflammation also 
reduces at the wound site indicating that the proliferative phase is underway. It 
is important to know that inflammation, if lasts longer than necessary will delay 
wound healing and result in a chronic wound. 
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PROLIFERATION:  
    This is the third phase of wound healing that roughly spans day 4 through 12 
post injury. It is also known as the phase of granulation, as a robust granulation 
tissue is formed during this period. This phase is characterized by numerous 
undefined and overlapping sub phases. These do not occur in a distinct time 
frame but represent an ongoing process, which stretch beyond the realms of the 
phase of proliferation. The major events in this phase are fibroplasia, matrix 
deposition, angiogenesis and re-epithelialization. 
     It is in this phase that the last cell populations of fibroblasts and endothelial 
cells invade the wound environment. After entering the wound, recruited 
fibroblasts proliferate and get activated in order to carry out their basic function 
of matrix synthesis and remodelling, which is mediated by cytokines and 
growth factors released by macrophages. Wound fibroblasts also aid in matrix 
contraction. In addition to cytokines, lactate, which is accumulated in wounds, 
also serves as a potent regulator of collagen synthesis via ADP ribosylation 
mechanism. Collagen plays a pivotal role in completion of the process of wound 
healing. Types I and III are absolute essentials for this, and its deposition, 
maturation and finally remodelling are necessary to restore the functional 
integrity of a healing wound. Early in normal wound healing, type III collagen 
predominates but as healing process progresses it is replaced by type I collagen. 
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FIGURE 3- STAGE OF PROLIFERATION 
 
    The wound at this stage is suffused with glycosaminoglycans and fibronectin 
synthesized by the fibroblasts. Glycosaminoglycans constitute most of the 
“ground substance” that makes up extra cellular matrix. They are found in the 
form of ‘proteoglycans’ in association with proteins. They peak during the first 
three weeks of wound healing. Assembly of collagen subunits as fibrils and 
fibres is based on the lattice structure provided by sulphated proteoglycans. 
Heparan sulphate, dermatan sulphate and chondroitin sulphate constitute the 
important glycosaminoglycans.  
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    Angiogenesis or neovascularization is a process that occurs concurrently with 
fibroblastic proliferation. It is initiated by the migration of endothelial cells to 
the wound area. They are attracted to the wound area by the fibronectin present 
in the fibrin scaffold and chemotactically by the angiogenic mediators secreted 
by inflammatory cells and fibroblasts. Tissue anoxia or hypoxia and 
accumulation of lactic acid in the wound also result in direct stimulation of 
endothelial cell growth and proliferation. When the macrophages and other 
growth factor synthesizing cells no longer encounter hypoxic and lactic acidotic 
surroundings, the manufacture of angiogenic factors is stopped. Excess vessels 
which are no longer required are destroyed by apoptosis. 
    The resultant of above processes put together is the formation of a 
rudimentary tissue called the granulation tissue. It appears in the wound already 
during the phase of inflammation; three to five days post injury, and continues 
to form until the wound bed is completely covered. Granulation is a 
conglomeration of freshly formed blood vessels, inflammatory cells, fibroblasts, 
myofibroblasts, endothelial cells and a provisional extra cellular matrix. This 
provisional extra cellular matrix mainly consists of fibronectin and hyaluronic, 
which create a well hydrate bed which facilitates cell proliferation. Later this 
provisional matrix is replaced by a mature one which consists mainly of 
glycosaminoglycans, collagen, elastin and glycoproteins aplenty.  
 
23 
 
MATURATION AND REMODELLING: 
    This phase begins during the fibroplastic phase, the characteristic feature of 
which is reorganization of already laid collagen. Collagen is disintegrated by 
matrix metalloproteinases and the total collagen content in a wound is the result 
of end product of difference between collagen synthesis and breakdown. Few 
weeks or months after injury, the amount of collagen reaches a plateau but there 
is a constant increase in the tensile strength for many more days. Fibril 
formation and cross linking result in reduced collagen solubility, increase in 
strength and enhanced resistance to degradation of the matrix by proteolytic 
enzymes. Remodelling continues from 6 months to 1 year post wounding, 
forming a mature, acellular and avascular scar. 
 
 RE-EPITHELIALIZATION: 
    In this phase, there is an attempt to restore the external barrier, characterized 
by proliferation and migration of cells from areas adjacent to the wound. It 
begins within a day of injury and continues throughout. Re-epithelialization is 
completely achieved in less than 48 hours in incised wounds but may take 
substantially longer in those which contain larger defects of dermis or 
epidermis. Exposure of epithelial cells in wound margins to the constituents of 
24 
 
extracellular matrix (namely fibronectin) and cytokines are believed to be the 
initiators of this process. 
    Basal keratinocytes from the edges of wounds and appendages of the skin 
such as sweat glands, sebaceous glands and hair follicles are the cells which 
epithelialize a healing wound. They migrate across the wound bed in a sheet, 
proliferate at edges and cease when they meet the cells from another side by 
contact inhibition. Integrins, matrix metalloproteases along with various growth 
factors aid in the process of keratinocyte migration and proliferation and 
formation of a healthy barrier. Wound healing is completed with some degree of 
contraction, observed more so in cases of healing by secondary intention. 
     The process of wound healing, thus, constitutes an array of inter-related and 
concomitant events. Understanding of these events and the factors affecting 
these events continues to expand rapidly. 
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PHASE 
 
CELLULAR AND HUMORAL EVENTS 
 
 
HEMOSTASIS 
 
Vasoconstriction 
Platelet aggregation, degranulation 
Formation of  Fibrin 
 
 
INFLAMMATION 
 
Neutrophil invasion 
Monocyte differentiation to Macrophages and  
    infiltration 
Lymphocyte influx 
 
 
PROLIFERATION 
 
Re-epithelialization 
Angioneogenesis 
Collagenogenesis 
Formation of Extra Cellular Matrix  
 
REMODELLING 
 
Collagen remodelling 
Vascular maturation and regression 
 
TABLE 1: PROCESS OF NORMAL WOUND HEALING  
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 FACTORS AFFECTING WOUND HEALING: 
    A number of intrinsic and extrinsic factors affect the process of wound 
healing, by interfering with one or multiple stages of healing thus causing 
inappropriate or impaired wound repair. A better understanding of these factors 
is of prime importance as the effects of these factors over healing process may 
lead to devising better therapeutics that resolve impaired wounds and improve 
wound healing. The influences of these factors over the healing process 
effectors are not mutually exclusive. Numerous adverse factors may act together 
complicating the scenario.  
    The factors adversely influencing wound healing can be broadly divided into: 
o Local factors 
o Systemic factors 
    Local factors influence the characteristics and cellular/ biochemical 
behaviour of the wound itself while the systemic factors affect a person’s 
overall health and ability to heal. Many of these factors can be interrelated as 
well. 
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LOCAL FACTORS SYSTEMIC FACTORS 
Hypoxia  
Infection 
Ischemia  
Venous insufficiency 
Foreign body 
Mechanical factors 
Edema  
Age   
Gender 
Sex hormones 
Stress 
Comorbid conditions 
Diabetes mellitus, Uremia, Connective 
tissue disorders 
Obesity 
Medications 
Corticosteroids, NSAIDS, Cancer 
chemotherapies 
Alcoholism and smoking 
Immunocompromised status 
AIDS, Radiation exposure 
Poor nutrition 
 
TABLE 2: FACTORS AFFECTING WOUND HEALING 
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 TYPES OF WOUND HEALING: 
Wound healing is classified into three major types, namely: 
o Healing by Primary Intention/ Primary wound healing 
o Healing by Secondary intention/ Secondary healing 
o Delayed primary healing 
    Even though wound healing is classified into different classes, the 
interactions of cellular/ extracellular components and biochemical parameters 
remain the same. 
 
PRIMARY HEALING: 
 
FIGURE 4: PRIMARY HEALING 
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    This type of healing is seen in a clean cut wound involving epidermis and 
dermis and not totally penetrating the dermis. The wound edges are close 
together in the wounds that eventually heal by primary intention. Most surgical 
wounds heal by this method and the healing is enhanced by use of sutures, 
staples etc. examples of wounds that heal by primary intention are- well 
repaired laceration, properly reduced fracture, healing after flap surgeries. These 
wounds scar minimally and show very less or no contracture. 
 
SECONDARY HEALING: 
 
 
FIGURE 5: SECONDARY HEALING 
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    Wounds healing with secondary intention exhibit a higher inflammatory 
response compared to primary healing. In this type, a full thickness, large 
wound is let alone to heal by granulation. Healing by secondary intention causes 
pronounced contraction of wounds. Fibroblastic differentiation into 
myofibroblasts, which are similar to contractile smooth muscles are postulated 
to contribute to contracture of healing wounds. Healing can be hampered by the 
presence of drainage from infection. Examples of healing by second intention 
are- venous ulcers, diabetic ulcers, gingivectomy, sockets after extraction of 
teeth and badly reduced fractures. 
DELAYED PRIMARY HEALING: 
 
 
FIGURE 6: TERTIARY HEALING 
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       This type of healing is desired in wounds that are contaminated. If the 
wound edges are not re-approximated immediately after a surgery/ traumatic 
event, delayed primary healing transpires. The wound is debrided, cleaned and 
deprived of necrotic material and foreign bodies and is deliberately left open for 
few days. The wound is then closed. Example of this type is healing by use of 
tissue grafts after thorough debridement and cleaning. 
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 CHRONIC WOUNDS: 
    Chronic wounds are defined as open wounds, which have failed to undergo 
the orderly set of stages of healing and re-epithelialization that produces a 
satisfactory structural and functional result. Wounds that have not healed in a 
period of about 3 months are termed as chronic. Chronic wounds seem to be 
arrested in one or more stages of wound healing. Most of the chronic wounds 
are found to remain in the inflammatory period for too long, as compared to a 
normally healing wound.  Unresponsiveness to normal regulatory signals is 
implicated as a major predictive feature of chronic wounds. 
    These wounds may take years to heal and sometimes, never heal. Along with 
the physical discomfort, chronic wounds also produce severe emotional and 
mental stress on the patients. They also impose heavy financial burden as the 
patients will undergo many therapies in order to gain relief, most of which are 
unsuccessful. 
  Causes of chronic wounds are enumerated as: 
o Hypoxia/ hypoperfusion 
o Anemia 
o Metabolic disorders 
o Nutritional disorders 
o Neuropathic disorders 
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o Steroids, chemotherapeutic drugs 
o Infections 
o Repeated trauma 
o Excessive inflammation 
    Typically, chronic wounds are clinically stagnant and fail to form a healthy 
and robust granulation tissue. 
    Chronic wounds are grossly classified as: 
o Vascular origin 
 Venous 
 Arterial 
o Diabetic ulcers 
o Pressure ulcers 
o Radiation induced 
o Miscellaneous 
 Ischemic, traumatic, iatrogenic etc. 
    Venous ulcers are a major cause of chronic leg wounds. They are the most 
common form of leg ulcers and constitute about 70- 90% of all leg ulcers. 
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 ANATOMY OF LOWER LIMB VENOUS SYSTEM: 
    The venous system of the lower limbs functions as a reservoir to hold extra 
blood as well as conduit to return blood from the peripheries. Unlike arteries, 
whose walls possess three distinct structural layers, most veins are made up of a 
solitary tissue layer. The effective functioning of a vein is dependent on a 
complex series of valves and pumps, which function as a unit.   
    The primary collecting veins of the lower limbs are passive, thin walled 
channels which are massively dilatable. They are suprafascial in situation, 
enclosed in loose areolar and fatty tissues which are easily displaced. These 
veins belong to the superficial venous system. Outflow from the superficial 
veins is into the secondary (conduit) veins that are less distensible and possess 
thicker walls. These veins are subfascial and constitute the deep venous system. 
 
- SUPERFICIAL VEINS: 
    The superficial venous system is a highly variable and complicated web-like 
network of interconnected veins, many of which are not named. A few large 
veins are fairly consistent in their anatomical location. Principal named 
superficial veins are the great saphenous vein (GSV) and the short saphenous 
vein (SSV). 
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GREAT SAPHENOUS VEIN: 
 
FIGURE 7: GREAT SAPHENOUS VEIN 
        The great saphenous vein has its origin in the medial part of foot from the 
dorsal venous arch and passes anterior to the medial malleolus. It runs in a 
posterior direction to ascend across the tibia medially towards knee. Above the 
knee it traverses an anteromedial course superficial to the deep fascia to reach  
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the foramen ovale. Here it pierces the cribriform fascia to join the common 
femoral vein at the saphenofemoral junction. Numerous named and unnamed 
tributaries drain into the great saphenous vein along its course. 
 
SHORT SAPHENOUS VEIN: 
    The short saphenous vein begins in the lateral part of the foot from the dorsal 
venous arch. 
 It passes across the lateral malleolus posteriorly and ascends lateral to the 
Achilles tendon to the calf. It lies in the midline in the calf, directly above the 
superficial fascia and traverses through to the upper part of calf, where it enters 
the popliteal space in between the two origins of gastrocnemius muscle. The 
termination site of short saphenous vein is highly variable. In two third of the 
population, it terminates in the popliteal vein above the knee joint.  
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FIGURE 8: SHORT SAPHENOUS VEIN 
 
    PERFORATING VEINS: 
    Most of the blood from the superficial veins is delivered to the deep veins via 
the saphenofemoral or the saphenopopliteal junctions. However, the SPJ and the 
SFJ are not the only means to carry out this task. Superficial veins are 
connected to numerous perforator veins that pierce the deep fascia and join deep 
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veins in calf as well as thigh. These perforator veins usually are valved, 
preventing reflux of blood from deep to superficial veins 
 
 
 
FIGURE 9: THE PERFORATOR VEINS 
  A few constant perforators are named, which represent a vague group of  
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perforating veins in that region, namely; 
o Hunterian perforator of mid-thigh 
o Dodd’s perforator present  in the distal thigh 
o Boyd’s perforator situated in  the knee 
o Cockett’s perforators at the ankle 
 
- DEEP VEINS: 
    The deep veins eventually receive all the venous blood from the superficial 
system and pass it to the major vessels of the pelvis. The important deep vein of 
the leg is the popliteal vein. The major deep vein of the thigh is formed by the 
continuation of the popliteal vein, called the femoral vein. 
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 CHRONIC VENOUS INSUFFICIENCY: 
    It is a condition where blood escapes its regular antegrade stream of flow in a 
vein and refluxes back into the preceding veins, rendering those veins dilated 
and insufficient. Venous insufficiency is most commonly due to the 
incompetence of the valvular system of superficial veins. Rarely, incompetence 
of deep veins and congenital conditions like absence of valves also contribute to 
the genesis of this condition. Chronic venous insufficiency leads to severe 
infections of the leg, pain especially after walking, and lipodermatosclerosis of 
the legs eventually resulting in skin ulceration. The burden of the disease along 
with poor cosmesis of this condition is distressing to the patient. 
 
PATHOPHYSIOLOGY: 
    Congenitally weak walls of a vein dilate even under normal pressures causing 
secondary valvular failure. Valves which are congenitally abnormal are 
incompetent at normal pressures. Superficial phlebitis or direct injury to the 
vessels/ valve may cause primary valve failure. Increased venous pressure is 
directly responsible for many aspects of chronic venous disease. The 
pathogenesis due to increased venous pressures can be described in a 
predictable sequence as shown below: 
 
41 
 
 
Increased venous pressure from venules to capillaries, impedance of flow 
 
Low pressure flow states in capillaries, results in “leucocyte trapping” 
 
Release of oxygen free radicles and proteolytic enzymes by the trapped 
leucocytes, damage to basement membrane of the capillaries 
 
Fibrinogen and other plasma proteins leak into the pericapillary areas, forming a 
“fibrin cuff” around the vessels 
 
 Fibrin in interstitium and subsequent edema prevent transport of oxygen to 
tissues leading to local hypoxia 
 
Inflammation and loss of tissues 
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    Another hypothesis states that the neutrophils which are stagnant in 
capillaries adhere to the endothelium and plug them, diminishing the dermal 
blood flow leading to ulceration and other complications. 
    Superficial veins develop a high pressure due to failure of critical valves at 
any point of communication between them and the deep veins. The major 
sources for high pressure leakage from the deep to the superficial veins are: 
i. JUNCTIONAL VALVE FAILURE: most frequently due to failure of 
valve between the great saphenous vein and the femoral vein at the 
saphenofemoral junction. Less commonly, it is due to the failure of the 
valve at the saphenopopliteal junction, present between the short 
saphenous vein and popliteal vein  
ii. PERFORATOR VALVE FAILURE: ensues as a result failure of any 
valves of perforator veins. 
    Venous hypertension and damage to capillaries lead to extravasation of 
haemoglobin and its degradation products which are harmful to the skin, acting 
as irritants. They cause skin damage as well as dark pigmentation, which along 
with loss of subcutaneous fat constitute lipodermatosclerosis, a characteristic 
feature of chronic venous disease. 
    It is necessary to note that not all the sequelae of venous insufficiency are due 
to venous hypertension and not every individual with it develops venous ulcers. 
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Few patients with prominent ulcers do not have evidence of venous 
hypertension. Ineffective clearance of products of cellular respiration, lactate 
and carbon dioxide also contribute to the genesis of chronic venous 
insufficiency and/or ulceration. The majority of venous ulcers are caused by 
venous reflux that is mostly limited to the superficial system of veins. Without 
addressing the underlying pathology, venous insufficiency is inexorably 
progressive. Subjective symptoms slowly worsen over time. 
 
 VENOUS ULCERS: 
“Ulcus Cruris Venosum” or venous ulcers are stasis ulcers, a dreaded 
complication of chronic venous insufficiency. Characteristically, a venous ulcer 
fails to re-epithelialize in spite of possessing adequate granulation tissue. 
Several ulcers may form and coalesce as they increase in size. They are usually 
found at sites of incompetent perforators. Most common site of venous ulcer is 
just above the medial malleolus (Cockett’s perforator). They are shallow, 
margins are irregular and surrounded by pigmented skin. 
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C.E.A.P CLASSIFICATION OF CHRONIC VENOUS DISORDERS 
    This is a comprehensive classification system involving the clinical, 
etiological, anatomical and pathophysiological parameters for chronic venous 
diseases. This severity score helps in the assessment of magnitude of ulcers and 
the venous disorder as whole. 
CLINICAL ETIOLOGY 
C0    - NO CLINICAL SIGNS 
C1    - TELANGIECTASIAS/   
              RETICULAR VEINS 
C2   - VARICOSE VEINS 
C3   - OEDEMA  
C4   - SKIN CHANGES, WITHOUT  
             ULCERS 
C5  - HEALED ULCERS 
C6  - ACTIVE ULCERS 
EC – CONGENITAL 
EP – PRIMARY 
ES - SECONDARY 
 
 
ANATOMY PATHOPHYSIOLOGY 
AS – SUPERFICIAL VEINS 
AD – DEEP VEINS 
AP – PERFORATORS 
PR – REFLUX 
PO - OBSTRUCTION 
 
TABLE 3: C.E.A.P CLASSIFICATION 
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 TREATMENT OPTIONS FOR VENOUS INSUFFICIENCY/ ULCERS: 
   Treatment of chronic venous ulcers is multimodal. No single therapy is found 
to be effective. The treatment is aimed at correcting the underlying causes if 
possible and more importantly, ameliorating symptoms. The primary intention 
of therapy is to address the issue of venous hypertension. Following are the 
common methods used for treatment: 
 
- COMPRESSION BANDAGING:  
    The standard approach has been to use gradient compression stockings 
around the leg and thigh. These provide 30-50 mm Hg of compression at 
the ankle, with a gradual decrease in compression pressure as it is applied 
more proximally. This amount of graded compression is enough to 
restore normal flow patterns in superficial veins in many or most patients 
with venous reflux. It is also known to improve venous flow, even in 
patients with severe incompetence of deep veins. 
    Along with compression therapy, other physical measures may also be 
helpful. Elevation of leg causes venous flow to be augmented by gravity, 
decreasing venous pressures and reversing edema. While seated, the 
patient’s legs should be above his/ her thighs and while recumbent, they 
should be above the level of the cardia. The Unna boot, first described in 
1854, is a common method of treatment of venous ulcers. Unna boots are 
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rolled bandages that contain combinations of different chemicals like 
glycerine, calamine lotion and gelatin.  
 
- VENOABLATION: 
    Venoablation is reserved for those with ulcers refractory to medical 
management or discomfort. The primary goal of endovenous and surgical 
interventions is to correct venous insufficiency by eliminating the major 
reflux pathways. Various techniques for venoablation include the 
following: 
o Ligation of GSV with stripping 
o Simple ligation and division of varicose veins 
o Stab evulsion (with or without ligation) 
o Sclerotherapy  
o Endovenous laser therapy (ELVIS) 
o Radiofrequency ablation 
    All methods of venoablation are effective. Once the overall venous 
reflux volume is brought down below a critical threshold, venous ulcers 
usually recover, and symptoms are alleviated. 
-     Other methods like local wound care, dressings, antibiotics, physical 
activity, prevention of standing for long periods, control of smoking etc. 
are also followed in every case. 
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-     Case specific treatment like split skin grafting for huge ulcers. 
 
-     NOVEL METHODS:  
o Alginates 
o Extracellular matrix 
o Iloprost 
o Sucralfate  
o Ultrasound patch 
o Nexagon etc. 
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SUCRALFATE: 
    Sucralfate is a cytoprotective molecule, which is employed in prevention and/ 
or treatment of diseases of gastrointestinal system such as peptic ulcer, stress 
ulcers, gastritis and gastro- esophageal reflux. Chemically, it is the aluminium 
hydroxide salt of sucrose octasulfate, the sulphated derivative of the 
disaccharide sucrose. Though it is related to sucrose, it is not utilized by the 
body as sugar. Sucralfate is also related to heparin but lacks any anticoagulant 
activity. It is known to have multiple beneficial effects influencing wound 
healing. The physical barrier character of sucralfate helps reduce inflammation 
and improve mucosal healing. Along with its cytoprotective action, stimulating 
effects on vascular factors which play a critical role in wound healing have been 
demonstrated.  
 
MOLECULAR MECHANISM OF SUCRALFATE: 
    Besides the ability of sucralfate to enhance the secretion and hydrophobicity 
of mucus gel in the gastric and duodenal mucosa and to bind bile acids, several 
other molecular mechanisms have been observed. These mechanisms are 
primarily responsible for the influence of sucralfate over wound healing. 
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FIGURE 10: MOLECILAR MECHANISM OF SUCRALFATE IN 
EPITHELIAL WOUND HEALING 
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i.  Increased growth factor bio availability:  
   It is now a well-known fact that chronic wounds lack growth factors 
and topical application of such factors would benefit the healing process.  
The long time required for growth factors to act on wounds may make 
them prone to degradation by proteases. Sucralfate binds to the likes of 
fibroblast growth factor, tumor growth factor β, vascular endothelial 
growth factor etc., preventing their protease mediated degradation. 
Sucralfate also promotes healing by increasing expression of receptors 
like human epidermal growth factor receptor. 
ii. Protection of cells apoptosis: 
    Inflammatory mediators and signals developed in damaged tissues are 
involved in cell apoptosis which is the main molecular cause of decrease 
in cellularity during stages of healing. Sucralfate is postulated to inhibit 
caspase- 3 activation, a major signal for apoptosis initiation. 
iii. Reduction of oxygen free radicals:  
    Oxygen free radicals inhibit wound healing by suppressing migration 
of cells and their proliferation by inducing cell apoptosis. It is now shown 
by studies that high concentrations of sucralfate inhibit these free radicals 
by an ischemia- reperfusion mechanism or direct contact with the free 
radical moieties. 
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iv. Antibacterial activity:  
    Sucralfate decreases the magnitude of translocation of bacteriae in 
several tissues, especially skin after injuries and preserves mucosal 
integrity. In the stomach, sucralfate also decreases the minimum 
inhibitory concentration of many antibiotics. 
v. Induction of prostaglandin production: 
    In vitro studies have effectively shown that sucralfate enhances the 
synthesis of prostaglandin E2 in basal keratinocytes and dermal 
fibroblasts and induce their proliferation. This helps in diminishing 
inflammation and enhanced wound healing.  
 
USES OF SUCRALFATE:  
 Gastric and duodenal ulcers- prevention and treatment. It is also used in 
the medical management of gastro-esophageal reflux. 
 Treatment of burns. 
 Venous stasis ulcers where sucralfate promotes neoangiogenesis and 
wound healing. 
 Treatment of peristomal skin excoriation/ ulceration. 
 Treatment of intertrigo. It is more effective when used with another 
adjuvant anti-inflammatory agent. 
 Treatment of non-neoplastic vaginal ulcers 
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 Treatment of aphthous ulcers, mucocutaneous lesions in disorders like 
Behcet’s disease.  
 Treatment of stomatitis and recurrent aphthous stomatitis. 
 Application over healing haemorrhoidectomy wounds. 
 Treatment of radiation induced acute skin reactions and dermatitis. 
 As enemas in control of radiation induced proctocolitis. 
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METHODOLOGY AND MATERIALS 
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METHODOLOGY 
STUDY DESIGN: prospective, comparative and interventional study 
    This study was conducted in the wards of Department of General Surgery, 
Coimbatore Medical College and Hospital, Coimbatore. 30 patients admitted 
with complaints of chronic venous or stasis ulcers are included the study in the 
period of 19-11-2012 to 18-11-2013. 
 
INCLUSION CRITERIA:  
 Chronic venous stasis ulcers in lower limbs 
  Non infected, clean ulcers 
EXCLUSION CRITERIA: 
   Neoplastic diseases 
   Hypersensitivity 
   Mixed wounds (Acute and chronic) 
   Acute or chronic renal failure 
   Pregnancy 
   Ulcers with underlying osteomyelitis 
   Thromboangitis obliterans 
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-      Co-morbidities like anaemia, hypertension and diabetes will be treated 
appropriately in all patients. 
-      Appropriate antibiotics will be given to prevent secondary infection 
and/or to treat co-existing infections systemically or in any similar 
lesions. 
-      Each patient is assigned to study group or control group by virtue of 
order of admission, i.e.: all even numbers will be allotted to case group 
and odd numbers to control group. 
-     Both groups will be treated with standard wound cleaning methods 
following which the cases under study group will receive topical 
sucralfate dressing, while the control group will receive topical saline 
dressing, once a day. 
-      All patients in both the groups will be treated with compression 
bandage therapy after application of sucralfate/ saline dressings. 
-      Dressings will be changed every day. In case of excessive soakage, 
dressing will be changed according to the need. 
-      Examination of the ulcer will be done with particular emphasis on size 
of the lesion, nature of granulation and relief of pain. The patients will be 
clearly instructed to make their own observations on decrease in size of 
the lesion and pain.  
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-      Dressing will be continued for 2 weeks, and the above mentioned 
parameters will be noted down using a visual scale by the investigator 
and a colleague (To minimize observation bias) on days 5, 10 and 14. 
-    Both the groups under study will be given appropriate treatment after 
the study period till their ulcers are healed. Both groups will also be 
treated with definitive procedures for underlying cause after the study 
period. 
-     All standard routine and specific investigations will be done in both the 
groups. 
-     For final analysis, the parametric values recorded on day 14 will be 
considered as it is most reliable and will give a definite picture of process 
of wound healing. However, the findings of day 5 and day 10 will be 
analysed as well, to monitor the progress of wound healing and efficiency 
of the treatment modality used. 
 
-      Results will be interpreted using the following observations made. 
 
1. SIZE OF THE ULCER: 
    It is noted in terms of whether the ulcer has decreased in size or 
remains the same. The dimensions are observed on three days by both 
the investigator and an observer colleague and any decrease in the 
size is noted with a “↓” mark. 
57 
 
SIZE OF THE ULCER 
DAY INVESTIGATOR OBSERVER 
5   
10   
14   
       The size of the ulcer is not assigned any scoring system as the 
size of the ulcers will be different in each individual and the rate of 
contraction of the wound cannot be easily standardized. 
 
2. GRANULATION: 
     This will be studied over the ulcer on all three days and computed 
as: 
 
GRANULATION 
DAY INVESTIGATOR OBSERVER 
5   
10   
14   
  
    A score of 2 is assigned for healthy granulation while 1 is assigned 
for absent or unhealthy granulation. The mean of final day 
observations of both the observers are taken for final analysis to avoid 
any subjective or observational bias. 
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3. DECREASE IN PAIN:  
    This parameter will be recorded on all three days as per the history 
given by the patient. All patients are clearly instructed to notice any 
changes in the magnitude of pain after the starting of therapy. 
 
DECREASE IN PAIN 
DAY INVESTIGATOR OBSERVER 
5   
10   
14   
 
   A score of 3 is assigned if there is good pain relief, 2 for moderate 
pain relief and 1 for minimal/ absent pain relief. The mean of final 
day observations are considered for analysis as explained earlier. 
-     The effect of sucralfate will be analysed and compared on all 3 days. 
-     Statistical analysis will be done using the final observation on day 14, 
using ‘Paired T Test’, given by the formula: 
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 The numerator of the formula is the sum of differences of all the 
values. 
 The denominator is the square root of n times the sum of the 
differences squared minus the sum of the squared differences, all over 
n-1. 
o ∑d2 = each difference in turn, square it, and add up all those 
squared numbers. 
o  (∑d) 2 = add up all the differences and square the result. 
-     Paired t test was selected for statistical analysis, as this study contains 
paired parametric data at different points of intervention. 
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MATERIALS 
        Sucralfate is soluble in strong acids and alkali but insoluble in polar 
solvents. It is insoluble in water. It reacts with acids like hydrochloric acid, 
forming an amorphous paste. It is known that sucralfate topical application is 
more effective in the form of a paste than slurry, which is formed if it is 
dissolved in water. The paste is prepared by incomplete reaction of sucralfate 
with an acid. This incomplete reaction negates the necessity of any further 
pharmaceutical steps. More importantly, the incomplete reaction results in the 
generation of a fully biologically active compound with no side effects or added 
effects of the solvent 
[12]
. 
    The incomplete reaction can be achieved through provision of quantity of 
acid sufficient enough to cause sucralfate polymerization. At the same time, 
care should be taken to restrict the total acid availability so as to prevent 
complete dissolution of sucralfate molecules. Stoichiometric experimentations 
and tests have resulted in the generalized consensus that it is ideal to subject 
approximately 5 gram of sucralfate to react with 2- 8 millimole of hydrochloric 
acid, at a concentration of 0.1N. The surface area of sucralfate available for 
contact with acid should be increased by finely powdering the sucralfate tablets. 
This will prevent the initial polymerization reaction at the surface which will 
hamper the polymerization of deep seated molecules. The resultant of this 
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reaction is a smooth and fine paste which can be stored in containers and used 
as topical application as desired. 
       For the purpose of use in this study, the sucralfate cream is prepared in the 
following way; 5 gram of sucralfate is well triturated to form a fine powder. To 
this powder, 1millilitre of 1.0N hydrochloric acid is added. The mixture is 
stirred constantly until it forms a fine paste. Few additional drops can be added 
in order smoothen the paste if required. Water can be added purely to aid in the 
process of mixing.  After formation of the paste, any excess fluid is washed off. 
The paste mass hence formed is smooth and less viscous. This paste should be 
kept covered in order to prevent drying. Alternatively, it can be stored in acid 
free water 
[12]
. 
 
TREATMENT PROTOCOL: 
    All the patients of both study and control group after admissions are 
subjected to the same initial assessment and evaluation. 
- Thorough clinical history is elicited and recorded. 
- Significant past history is noted. 
- Any cases coming under the realm of exclusion criteria are omitted and 
the next patient is considered in that place. 
- Detailed clinical examination is performed. 
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- Local examination of the ulcer is performed with emphasis on size and 
granulation. Co-existing infections noted if any. 
- Thorough wound debridement is done in both the groups till all the 
devitalized tissues are removed. 
- Antibiotics are administered only if necessary. 
- Once the wound is ready for the further management, the study cases are 
treated with daily application of sucralfate gel, while the control cases are 
treated with saline dressing. 
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RESULTS and discussion 
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  Study was conducted on 30 patients admitted after analysing the nature of the 
wound according to the inclusion and exclusion criteria described. Patients were 
randomized as mentioned before and treated accordingly. All patients were 
followed up for the complete study period with no defaulters or drop-outs in 
either the study or the control groups. 
    Both cases and controls were observed for parametric analysis on days 5, 10 
and 14. Results tabulated by both the observers were compared and a mean 
score obtained to avoid bias. Patients were also followed up for a period of 2 
months afterwards to ensure there were no recurrences of complications. 
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I. SEX DISTRIBUTION 
 
   
 
TOTAL CASES 30 
MALES 26 
FEMALES 4 
 
 
87% 
13% 
SEX DISTRIBUTION 
MALE
FEMALE
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II. AGE DISTRIBUTION 
 
     
NUMBER OF PATIENTS < 20 YEARS 0 
NUMBER OF PATIENTS AGED 21- 30 2 
NUMBER OF PATIENTS AGED 31- 40 6 
NUMBER OF PATIENTS AGED 41- 50 19 
NUMBER OF PATIENTS AGED 51- 60 2 
NUMBER OF PATIENTS AGED > 60  1 
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    This chart shows that venous ulcers are seen maximum in the 5
th
 decade of 
life, followed by the 4
th
 decade. 
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III. DECREASE IN SIZE OF ULCER 
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CHART COMPARING 14
TH
 DAY OUTCOME OF CASE V/S CONTROL IN 
DECREASE IN ULCER SIZE 
  
   These charts show the superiority of sucralfate in decreasing the ulcer size 
effectively. The 14
th
 day graphs clearly exhibit the difference in the 
performance of both sucralfate and saline dressing. 
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PERCENTAGE CHARTS OF PATIENTS WITH DECREASE IN ULCER 
SIZE IN STUDY CASES V/S CONTROL 
 
 STUDY 
CASES 
CONTROL 
TOTAL CASES 15 15 
NUMBER SHOWING 
DECREASE ON DAY 14 
12 2 
RESPONSE [IN %] 80% 14% 
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IV. GRANULATION 
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CHART SHOWING 14
TH
 DAY OBSERVATION ON GRANULATION IN 
CASES V/S CONTROLS 
 
    The above 3 charts show that sucralfate helps wounds granulate at a faster 
rate compared to standard saline dressing. 
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PERCENTAGE CHARTS OF PATIENTS SHOWING HEALTHY 
GRANULATION IN STUDY CASES V/S CONTROL 
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V. DECREASE IN PAIN 
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CHART SHOWING 14
TH
 DAY OBSERVATION OF DECREASE IN PAIN- 
CASE V/S CONTROL 
 
     The above charts clearly indicate that sucralfate cause reduction in pain over 
the ulcer at a rate higher than saline dressed wounds. 
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PERCENTAGE CHARTS OF PATIENTS WITH DECREASE IN PAIN IN 
STUDY CASES V/S CONTROL 
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CHART DEPICTING OBSERVATIONS OF RESPONSE TO SUCRALFATE 
WITH RESPECT TO DECREASE IN PAIN ON ALL DAYS 
   
  It can be noted that as the time goes on, the response improves, that is many 
patients experience reduction in pain. 
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STATISTICAL ANALYSIS 
    The variables were analysed statistically based on the 14
th
 day observation 
values and it was tested by ‘paired t test’.  
-   As mentioned earlier, the decrease in size of ulcer was not assigned any 
scoring due to difficulties in standardization. It was assessed on the basis 
of visual observation and quality of the wound. 
-   Granulation scores were tabulated and the scores of final observation 
were considered. Mean of the scores obtained from both the observers 
were subjected to the paired t test and the following results were 
obtained. 
 
 
 
GRANULATION 
MEAN S.D NUMBER 
GROUP 
CONTROL 1.23 0.42 15 
STUDY 2.03 0.30 15 
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GRAPH 1: MEAN SCORES FOR GRANULATION- STUDY 
CASES V/S CONTROL 
 
 TEST FOR EQUALITY OF MEANS 
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DF 
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P < 0.01 
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- Decrease in pain over the ulcer was dealt with in similar way and the 
following results were obtained. 
 
 
DECREASE IN PAIN 
MEAN S.D NUMBER 
GROUP 
CONTROL 1.07 0.26 15 
STUDY 2.13 0.64 15 
 
 
 
GRAPH 2: MEAN SCORES FOR DECREASE IN PAIN 
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 TEST FOR EQUALITY OF MEANS 
 
 
t 
 
DF 
 
PROBABILITY 
 
SIGNIFICANCE 
 
5.987 
 
28 
 
0.001 
 
P < 0.01 
 
 
P VALUE OF BOTH THE TESTS = LESS THAN 0.01 
                                                               (P < 0.01) 
Hence the study is statistically significant at 1% interval 
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DISCUSSION 
 
    Chronic venous ulcer is an important surgical condition due to the high 
incidence and lack of a standard therapeutic protocol. The care of chronic 
venous ulcers often relies on palliative and mostly unsuccessful therapies. Apart 
from surgical approach, a variety of medical therapies to influence wound repair 
and regeneration are currently being investigated. Topical drugs in this regard 
have proven to be promising and very useful in treatment of chronic venous 
ulcers. It is now clear that wound healing is a complex procedure dependent on 
angiogenesis, cell proliferation, extracellular matrix remodelling, tissue 
inflammation and good re-epithelialization. Thus the ideal drug to treat such 
ulcers should possess properties to enhance all these parameters. 
    Sucralfate is a cytoprotective agent, which is extensively used in treatment or 
prevention of several gastrointestinal tract related diseases such as 
gastroesophageal reflux disease, gastritis, dyspepsia, gastric and duodenal 
ulcers, stress ulcer and in the treatment of recurrent aphthous stomatitis. Recent 
studies have shown the stimulating effect of sucralfate over EGF expression and 
expression of other growth factors involved in tissue repair processes. 
Furthermore, the stimulating effects of sucralfate on vascular factors, including 
angiogenesis have been well demonstrated. Several studies have also shown that 
sucralfate increases wound contraction, re-epithelialization and diminishes 
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inflammatory reactions. It is safe and well tolerated, as demonstrated by 
complete lack of side effects. 
    The recent case reports and sporadic study- analyses are coherent and 
consistently indicate the favourable and effective influence of topical sucralfate 
in wound healing. A pilot study 
[1]
 with topical sucralfate on full thickness, non-
healing venous stasis ulcers (even after 8 weeks of therapy with other 
modalities) showed very encouraging results. This study was conducted on a 
group of 9 patients while Tumino et al 
[2]
 expanded this number in another study 
to 100 patients. All the cumulative data provided enough supportive evidence to 
conduct this study. 
   Our study consisted of 30 patients randomly selected. 26 of the patients were 
male which comprises 87% of the study population and 4 of them females, 
which is 13% of the total study population.  Most of these patients are in the 5
th
 
decade of life, closely followed by the late forties age group. The worldwide 
statistics show that venous ulcer is a common disease of the adults and elderly, 
and our study is in tune with that. More than half of the study population is 
above the age of forty (63%).  
    12 out of the 15 study cases, that is 80% of the study population exhibited 
decrease in size of the ulcer at the end of 14 days while only 2 in the control 
group reported a decrease in the size. This is consistent with the study by 
Tumino et al 
[2] 
where 43 out of 45 study population (95.6%) exhibit dramatic 
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complete cure of the ulcer with topical sucralfate application for a period of 40 
days, as against 5 out of the 46 (11%) control population who were treated with 
a placebo. This finding is also potentiated by other studies concerning various 
types of epithelial lesions, where the patients using topical sucralfate have 
demonstrated complete cure or a healthy remission. These studies include ulcers 
due to radiation, vaginal ulceration, second and third degree burns etc. 
[3, 4, 5, 6, 7, 
8, 9, and 10]
 
 
 
 
PHOTOGRAPH 1: CHRONIC VENOUS ULCER BEFORE TREATMENT 
WITH TOPICAL SUCRALFATE 
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PHOTOGRAPH 2: HEALTHY GRANULATION AFTER TREATMENT 
WITH TOPICAL SUCRALFATE IN A PATIENT 
 
     Analysis of the granulation tissue over the ulcer bed revealed that 12 out of 
the 15 study cases, that is 86% of the study population developed very healthy 
granulation over the wound and eventually achieved good re-epithelialization. 
On the contrary, only 2 out of 15 patients from the control group, that is 14% of 
total control population, developed good granulation tissue. The remainder 
continued to exhibit the non-healing nature of the ulcer. This finding is again 
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consistent with the study by Tumino et al 
[2]
, which showed healthy granulation 
and/or total cure in 43 out of 45 study cases (95.6%), while the control group 
consisted only 4 out the 46 patients showing cure with placebo, that is 8.6% of 
the total control population.  
    Statistical analysis of the same was also comparable to the results of study by 
Tumino et al 
[2]
, the mean score for granulation in that being 2.5 and in our 
study the same was 2.03. ‘p’ value for the analysis of granulation in the study 
by Tumino et al 
[2]
 was 0.0001 which is statistically significant. The ‘p’ value 
for granulation in our study is < 0.01 which is statistically significant. The 
results of our study is also comparable to other studies, namely by Tsakayannis 
et al 
[1]
. Lentz 
[8]
 and Banati et al 
[10]
, which showed the significant influence of 
topical sucralfate over other types of epithelial wounds. 
    Analysis of decrease in pain over the ulcer in our study shows that 13 out of 
the 15 study cases, that is 93% showed noteworthy improvement in the nature 
and magnitude of pain. Only 1 out of the 15 control subjects, that 7% of the 
total control population showed significant decrease in pain. This is again 
coherent with the study by Tumino et al 
[2]
, which showed decrease of pain in 
42 out of the 45 study cases (93.3%) and 4 out of 46 controls (8.7%). The mean 
score for pain reduction in our study is 2.13 for study subjects while that of the 
control group is 1.07. In the study by Tumino et al 
[2], the ‘p’ value for this 
parametric study is 0.0023, while in our study it is < 0.01 showing the statistical 
significance. 
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PHOTOGRAPH 3: AFTER ONE MONTH TREATMENT WITH TOPICAL 
SUCRALFATE IN A PATIENT 
 
    Overall, the cumulative results of this study indicate that sucralfate has a 
positive and curative influence over chronic venous ulcers. It is effective in 
promoting wound healing process and re-epithelialization and is also safe for 
topical application. Patients suffering from chronic venous ulcers can benefit 
from the use of topical sucralfate. 
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CONCLUSIONS 
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In this study:   
-     The majority of the patients belonged to the fifth decade of life. 
-    Male predominance was observed in both the groups.  
-    All the patients had received treatment for the condition by one or the 
other approved method and did not obtain any cure prior to this study. 
-     Sucralfate in the topical application form showed favourable results in 
healing a chronic venous ulcer by promoting healthy granulation and 
good re-epithelialization. 
-     Subjective symptoms of the patient, most important of which being 
pain, was effectively reduced by topical sucralfate. 
-     The efficacy of sucralfate in treatment of chronic ulcers and epithelial 
wounds are statistically significant, which is consistent with a multitude 
of worldwide studies. 
-     Sucralfate topical gel is easy to prepare [11,12], easy to store and easy to 
use 
-     The preparation of topical gel does not involve high costs and can be 
easily afforded. 
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     Chronic venous ulcer still remains a hard nut to crack for the surgeons, 
owing to its complex pathophysiology, debilitating course and limited treatment 
options. The research and trials into the various modalities of treatment are 
ongoing, but there is a need to find a solution which is effective and less 
financially burdening to the patients. The current study involved a small group 
of patients but showed promising and encouraging results with respect to wound 
granulation, epithelialization and decrease in subjective symptoms. Sucralfate 
being an inexpensive drug lessens the need for heavy expenditure, considering 
the financial burden a patient has to bear when getting a chronic ulcer treated. 
    We conclude that sucralfate can be one such alternative solution to this age 
old problem and deserves thorough research, exploration and evaluation in this 
regard. 
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APPENDIX II – PROFORMA 
 
NAME:            
AGE/ SEX:          DOA: 
OCCUPATION:                 DOD: 
ADDRESS:  
CHIEF COMPLAINTS: 
1. Ulcer over legs - onset and progress 
2. H/O trauma 
 
PAST HISTORY 
1. H/O DM/ HTN/ Asthma/  TB/ Epilepsy 
2. H/O malignancy/irradiation. 
3. H/O chronic cardiac disease/chronic liver disease/ chronic renal disease/ 
vasculitis 
 
PERSONAL HISTORY: 
    H/O of present conception 
    Smoking/ Alcoholism 
    Bowel and bladder habits 
    Sleep pattern. 
 
GENERAL PHYSICAL EXAMINATION: 
1. Hydration 
2. Nutritional status 
3. Pallor  
4. Icterus  
5. Cyanosis/ clubbing/ edema 
6. Generalized/ regional lymphadenopathy 
7. Pulse rate 
8. Blood pressure. 
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SYSTEMIC EXAMINATION: 
 CARDIOVASCULAR SYSTEM: 
 Inspection 
         Auscultation 
 RESPIRATORY SYSTEM: 
Inspection  
         Percussion  
         Auscultation 
 CENTRAL NERVOUS SYSTEM: 
Consciousness 
         Orientation 
 Higher mental functions 
 
 PER ABDOMEN:  
Inspection 
        Auscultation 
   
LOCAL EXAMINATION: 
 INSPECTION:  Number, site, extent, shape, size. 
                         Margin- undermined, punched out, sloping, raised/ 
rolled out or raised/ everted 
                         Floor of the ulcer 
                        Discharge 
                       Adjacent area 
 PALPATION: Temperature, tenderness, margin for induration, base for 
underlying structure and mobility. 
 Examination for any regional lymph nodes, vascular diseases, nerve 
lesions and tuberculosis. 
 
DIAGNOSIS: 
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INVESTIGATIONS:  
- Complete hemogram, random blood sugar, blood urea, serum creatinine, 
serum electrolytes. 
- Liver function tests, serum proteins 
- Pus culture and sensitivity  
- Electrocardiogram. 
- Chest radiograph. 
-Test for HIV 1 &11; HBsAg 
-And relevant investigations for associated medical conditions 
 
 
SAFETY CONSIDERATIONS:  
The safety of the patients will be foremost. The procedures of taking blood 
samples will be under aseptic conditions using necessary precautions. All 
procedures done, both operative and non-operative will be done after the due 
consent of the patient or his/her attendant 
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CONSENT FORM 
 
    It has been explained to me in my mother tongue and I completely understand 
my condition, its related complications and the treatment options available. I 
have been explained in detail regarding this study- “TREATMENT OF 
CHRONIC VENOUS ULCERS WITH TOPICAL SUCRALFATE”. I hereby 
give my voluntary and willful consent to participate in the above mentioned 
study. 
DATE:                                                                              PLACE: 
 
 
  SIGNATURE OF THE                                               SIGNATURE OF THE 
          PATIENT                                                                     RELATIVE 
     (WITH NAME)                                                             (WITH NAME) 
 
                                            SIGNATURE OF THE 
                                                     WITNESS 
                                                 (WITH NAME) 
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MASTER CHART 
 
 
 
NAME AGE SEX STUDY 
GROUP 
OBSERVATION 
DAYS 
DECREASE IN SIZE GRANULATION DECREASE IN PAIN TOTAL SCORE 
I II I II I II 
 
1 
 
KARUPPATHAL 
 
46 
 
F 
 
CASE 
5 - - 1 1 1 1 
G- 2 
P- 1 
10 ↓ ↓ 2 2 1 1 
14 ↓ ↓ 2 2 1 1 
 
2 
 
PALANIVELU 
 
47 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 2 
P- 1 
10 - - 1 1 1 1 
14 - - 2 2 1 1 
 
3 
 
DANIEL 
 
42 
 
M 
 
CASE 
5 - - 2 2 1 1 
G- 2 
P- 2 
10 ↓ ↓ 2 2 1 1 
14 ↓ ↓ 2 2 2 2 
 
4 
 
RAMACHANDRAN 
 
50  
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
 
5 
 
NAGARAJ 
 
52 
 
M 
 
CASE 
5 - - 2 2 1 1 
G- 2 
P-2 
10 - - 2 2 1 1 
14 - - 2 2 2 2 
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6 
 
JAWAHAR ALI 
 
35 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 ↓ ↓ 1 1 1 1 
 
7 
 
ANNAMALAI 
 
46 
 
M 
 
CASE 
5 - - 1 1 1 1 
G- 2 
P- 1 
10 - - 2 2 1 1 
14 ↓ ↓ 2 2 1 1 
 
8 
 
MANI 
 
42 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P-1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
 
9 
 
GOVINDARAJ 
 
32 
 
M 
 
CASE 
5 ↓ ↓ 2 2 1 1 
G- 2  
P- 3 
10 ↓ ↓ 2 2 1 1 
14 ↓ ↓ 2 2 3 3 
 
10 
 
BALAMURUGAN 
 
42 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
 
11 
 
DHARMALINGAM 
 
55 
 
M 
 
CASE 
5 - - 1 1 1 1 
G- 1.5 
P- 1 
10 - - 1 1 1 1 
14 ↓ ↓ 2 1 2 2 
 
12 
 
KARUN KANNAN 
 
 
29 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 2  
P- 2 
10 - - 2 2 2 2 
14 ↓ ↓ 2 2 2 2 
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13 
 
MARIYA BEGUM 
 
36 
 
F 
 
CASE 
5 - - 1 1 1 1 
G- 2  
P= 3 
10 - - 2 1 3 3 
14 ↓ ↓ 2 2 3 3 
 
14 
 
SIVARAMAN 
 
47 
 
M 
 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
 
15 
 
MURUGESAN 
 
41 
 
M 
 
CASE 
5 - - 1 1 1 1 
G- 2 
P- 2 
10 - - 2 2 1 1 
14 - - 2 2 2 2 
 
16 
 
SRIJIL 
 
42 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 2  
P- 1 
10 - - 1 1 1 1 
14 - - 2 2 1 1 
 
17 
 
ABU TAHIR 
 
39 
 
M 
 
CASE 
5 - ↓ 1 1 1 1 
G- 2 
P- 3 
10 ↓ ↓ 2 2 2 2 
14 ↓ ↓ 2 2 3 3 
 
18 
 
SIVA LAKSHMI 
 
41 
 
F 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P-1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
 
19 
 
KARUPPUSAMY 
 
 
72 
 
M 
 
CASE 
5 - - 1 2 1 1 
G- 2 
P- 2 
10 - - 1 2 2 2 
14 - - 2 2 2 2 
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20 
 
MUTHU KUMAR 
 
43 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1.5 
P- 1 
10 - - 1 1 1 1 
14 -        - 1 2 1 1 
 
21 
 
TAMILAN 
 
22 
 
M 
 
CASE 
5 - - 1 1 1 1 
G- 2 
P- 2 
10 - - 2 2 2 2 
14 ↓ ↓ 2 2 2 2 
 
22 
 
FRANCIS 
 
34 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 2 
14 - - 1 1 1 1 
 
23 
 
PARTHIBAN 
 
41 
 
M 
 
CASE 
5 - - 2 2 1 1 
G- 2 
P- 2 
10 ↓ ↓ 2 2 1 1 
14 ↓ ↓ 2 2 2 2 
 
24 
 
SINGARAM 
 
41 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 2 1 1 
14 - - 1 1 1 1 
 
25 
 
RAJENDRAN 
 
49 
 
M 
 
CASE 
5 - - 2 2 1 1 
G- 2 
P- 3 
10 - - 2 2 1 2 
14 - - 2 2 3 3 
 
26 
 
MANNAM 
 
 
42 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
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27  
VIVEK 
 
33 
 
M 
 
CASE 
5 - - 1 1 1 1 
G- 2 
P- 2 
10 ↓ ↓ 2 2 1 1 
14 ↓ ↓ 2 2 2 2 
28  
VIGHNESHWARI 
 
48 
 
F 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
29  
SARAVANAN 
 
41 
 
M 
 
CASE 
5 ↓ ↓ 1 1 1 1 
G- 2 
P- 2 
10 ↓ ↓ 2 2 1 1 
14 ↓ ↓ 2 2 2 2 
30  
RAJU 
 
44 
 
M 
 
CONTROL 
5 - - 1 1 1 1 
G- 1 
P- 1 
10 - - 1 1 1 1 
14 - - 1 1 1 1 
        
** G = GRANULATION 
      P = DECREASE IN PAIN 
 

